HSD112 Uptake of Newer Second-Line Diabetes Medications in Real-World Vulnerable Populations

Editorial Diabetes in Socioeconomically Vulnerable Populations

Diabetes mellitus (DM) is a global epidemic that is increasing rapidly. An estimated 415 million people worldwide currently live with DM and another 318 million people have impaired glucose tolerance (IGT), a marker for future DM. By 2040 these numbers are likely to grow to 642 million and 481 million, respectively. Over 75% of prevalent cases live in low and middle income countries. Economic t...

Second-line agents for glycemic control for type 2 diabetes: are newer agents better?

OBJECTIVE While metformin is generally accepted as the first-line agent in treatment of type 2 diabetes, there are insufficient evidence and extensive debate about the best second-line agent. We aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens considering clinical effectiveness, quality of life, and cost. RESEARCH DESIGN AND METHODS We develope...

Vulnerable Populations: Vulnerable People

the tragedy of modern man in arthur millers world

what miller wants is a theatre of heightened consciousness. he speaks of two passions in a man, the passion to "feel" and the passion "know". he belives that we can have more of the latter. he says: drama is akin to the other inventions of man in that it ought to help us know more and not merely to spend our feelings. the writing of the crucible shows us that he is trying to give more heightene...

Tiotropium safety in ‘real‐world’ populations

We read with interest the publication of Schmiedl et al. describing the characteristics of patients treated with tiotropium HandiHaler or Respimat in the Tiotropium Safety and Performance in Respimat (TIOSPIR) study compared with their ‘real-world’ database [1]. The authors noted that patients starting either treatment had similar characteristics but suggest that we may have included a selected...